In addition, the activity of FOXO1 has been reported to affect the antineoplastic drug sensitivity of AML cells, and has been proposed as a therapeutic for leukemia with RUNX1 mutations [40, 41]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.